Hideki Oizumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hideki Oizumi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Takeda
Department of Neurology National Hospital Organization Sendai Nishitaga Hospital Sendai Japan
4 shared publications Kohji Fukunaga
Department of CNS Drug Innovation, Tohoku University Graduate School of Pharmaceutical Sciences, 6-3, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan
3 shared publications- Takafumi Hasegawa
Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan
3 shared publications Yoko Sugimura
Department of Neurology, National Hospital Organization Sendai Nishitaga Hospital, 2-11-11, Kagitorihoncho, Taihaku-ku, Sendai, Miyagi 982-8555, Japan
3 shared publicationsSaki Ohshiro
Affiliation Department of Neurology, National Hospital Organization Sendai Nishitaga Hospital, Sendai, Japan
2 shared publicationsTakafumi Hasegawa
Affiliation Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
2 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Elsevier in SSRN Electronic Journal
A Serum Neurofilament Light-Based Risk Score Predicts Cognitive Decline in Early Parkinson’s Disease: A Longitudinal Parkinson’s Progression Markers Initiative Study
Background: The progression of Parkinson’s disease (PD), particularly cognitive decline, is substantially heterogeneous. Serum neurofilament light chain (NfL) is a useful biomarker of neurodegeneration, and PD patients with high serum NfL levels are more likely to develop dementia.Objective: We investigated whether a composite risk score (sNfL-Risk score) that combines serum NfL with age, cognition, motor severity, and RBD-related symptoms can predict cognitive decline in PD.Methods: We conducted a prospective cohort study using datasets from the Parkinson’s Progression Markers Initiative (PPMI). The sNfL-Risk score was constructed by integrating scores for serum NfL, age, MoCA, UPDRS part III, and RBDSQ. Associations between the sNfL-Risk score and cognitive decline were evaluated using logistic regression and net reclassification improvement (NRI) analyses.Results: A strong association was observed between higher sNfL-Risk scores and an increased risk of cognitive decline at 5 years. Each 1-point increase in the sNfL-Risk score was associated with 2.65-fold greater odds of cognitive decline at 5 years (95% Confidence interval (CI) 2.12–3.32; p < 0.0001). The higher the risk score was, the more significantly the probability of cognitive decline within 5 years increased, exceeding 48% in patients with scores ≥3. Compared with NfL alone, the sNfL-Risk score performed better in predicting cognitive decline (AUC 0.8 vs. 0.684; p < 0.0001) and demonstrated superiority in risk stratification (categorical NRI 0.255; p = 0.006).Conclusions: The sNfL-Risk score may be useful for stratifying patients at risk of PD-related cognitive decline and may contribute to the development of personalized management strategies.
- 25 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Serum Neurofilament Light-Based Risk Score Predicts Cognitive Decline in Early Parkinson’s Disease: A Longitudinal Parkinson’s Progression Markers Initiative Study
Background: The progression of Parkinson’s disease (PD), particularly cognitive decline, is substantially heterogeneous. Serum neurofilament light chain (NfL) is a useful biomarker of neurodegeneration, and PD patients with high serum NfL levels are more likely to develop dementia.Objective: We investigated whether a composite risk score (sNfL-Risk score) that combines serum NfL with age, cognition, motor severity, and RBD-related symptoms can predict cognitive decline in PD.Methods: We conducted a prospective cohort study using datasets from the Parkinson’s Progression Markers Initiative (PPMI). The sNfL-Risk score was constructed by integrating scores for serum NfL, age, MoCA, UPDRS part III, and RBDSQ. Associations between the sNfL-Risk score and cognitive decline were evaluated using logistic regression and net reclassification improvement (NRI) analyses.Results: A strong association was observed between higher sNfL-Risk scores and an increased risk of cognitive decline at 5 years. Each 1-point increase in the sNfL-Risk score was associated with 2.65-fold greater odds of cognitive decline at 5 years (95% Confidence interval (CI) 2.12–3.32; p < 0.0001). The higher the risk score was, the more significantly the probability of cognitive decline within 5 years increased, exceeding 48% in patients with scores ≥3. Compared with NfL alone, the sNfL-Risk score performed better in predicting cognitive decline (AUC 0.8 vs. 0.684; p < 0.0001) and demonstrated superiority in risk stratification (categorical NRI 0.255; p = 0.006).Conclusions: The sNfL-Risk score may be useful for stratifying patients at risk of PD-related cognitive decline and may contribute to the development of personalized management strategies.
- Open Access
- 7 January 2026
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 14
Temporal patterns of motor and nonmotor symptom emergence in Parkinson’s disease: a cluster analysis
- 7 January 2026
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 14
Open AccessTemporal patterns of motor and nonmotor symptom emergence in Parkinson’s disease: a cluster analysis
- Open Access
- 11 March 2025
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 12, 100313
Associations among blood biomarkers, clinical subtypes, and prognosis in Parkinson’s disease
- 11 March 2025
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 12, 100313
Open AccessAssociations among blood biomarkers, clinical subtypes, and prognosis in Parkinson’s disease
- Open Access
- 16 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0279315
Plasma sphingolipid abnormalities in neurodegenerative diseases
Background: In recent years, there has been increasing evidence that several lipid metabolism abnormalities play an important role in the pathogenesis of neurodegenerative diseases. However, it is still unclear which lipid metabolism abnormalities play the most important role in neurodegenerative diseases. Plasma lipid metabolomics (lipidomics) has been shown to be an unbiased method that can be used to explore lipid metabolism abnormalities in neurodegenerative diseases. Plasma lipidomics in neurodegenerative diseases has been performed only in idiopathic Parkinson’s disease (IPD) and Alzheimer’s disease (AD), and comprehensive studies are needed to clarify the pathogenesis. Methods: In this study, we investigated plasma lipids using lipidomics in individuals with neurodegenerative diseases and healthy controls (CNs). Plasma lipidomics was evaluated by liquid chromatography-tandem mass spectrometry (LC–MS/MS) in those with IPD, dementia with Lewy bodies (DLB), multiple system atrophy (MSA), AD, and progressive supranuclear palsy (PSP) and CNs. Results: The results showed that (1) plasma sphingosine-1-phosphate (S1P) was significantly lower in all neurodegenerative disease groups (IPD, DLB, MSA, AD, and PSP) than in the CN group. (2) Plasma monohexylceramide (MonCer) and lactosylceramide (LacCer) were significantly higher in all neurodegenerative disease groups (IPD, DLB, MSA, AD, and PSP) than in the CN group. (3) Plasma MonCer levels were significantly positively correlated with plasma LacCer levels in all enrolled groups. Conclusion: S1P, Glucosylceramide (GlcCer), the main component of MonCer, and LacCer are sphingolipids that are biosynthesized from ceramide. Recent studies have suggested that elevated GlcCer and decreased S1P levels in neurons are related to neuronal cell death and that elevated LacCer levels induce neurodegeneration by neuroinflammation. In the present study, we found decreased plasma S1P levels and elevated plasma MonCer and LacCer levels in those with neurodegenerative diseases, which is a new finding indicating the importance of abnormal sphingolipid metabolism in neurodegeneration.
- 16 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0279315
Open AccessPlasma sphingolipid abnormalities in neurodegenerative diseases
Background: In recent years, there has been increasing evidence that several lipid metabolism abnormalities play an important role in the pathogenesis of neurodegenerative diseases. However, it is still unclear which lipid metabolism abnormalities play the most important role in neurodegenerative diseases. Plasma lipid metabolomics (lipidomics) has been shown to be an unbiased method that can be used to explore lipid metabolism abnormalities in neurodegenerative diseases. Plasma lipidomics in neurodegenerative diseases has been performed only in idiopathic Parkinson’s disease (IPD) and Alzheimer’s disease (AD), and comprehensive studies are needed to clarify the pathogenesis. Methods: In this study, we investigated plasma lipids using lipidomics in individuals with neurodegenerative diseases and healthy controls (CNs). Plasma lipidomics was evaluated by liquid chromatography-tandem mass spectrometry (LC–MS/MS) in those with IPD, dementia with Lewy bodies (DLB), multiple system atrophy (MSA), AD, and progressive supranuclear palsy (PSP) and CNs. Results: The results showed that (1) plasma sphingosine-1-phosphate (S1P) was significantly lower in all neurodegenerative disease groups (IPD, DLB, MSA, AD, and PSP) than in the CN group. (2) Plasma monohexylceramide (MonCer) and lactosylceramide (LacCer) were significantly higher in all neurodegenerative disease groups (IPD, DLB, MSA, AD, and PSP) than in the CN group. (3) Plasma MonCer levels were significantly positively correlated with plasma LacCer levels in all enrolled groups. Conclusion: S1P, Glucosylceramide (GlcCer), the main component of MonCer, and LacCer are sphingolipids that are biosynthesized from ceramide. Recent studies have suggested that elevated GlcCer and decreased S1P levels in neurons are related to neuronal cell death and that elevated LacCer levels induce neurodegeneration by neuroinflammation. In the present study, we found decreased plasma S1P levels and elevated plasma MonCer and LacCer levels in those with neurodegenerative diseases, which is a new finding indicating the importance of abnormal sphingolipid metabolism in neurodegeneration.
- Open Access
- 24 June 2022
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 9 (8) , 1136-1146
Phosphorylated alpha‐synuclein in Iba1‐positive macrophages in the skin of patients with Parkinson's disease
Background: Increasing evidence suggests that alpha‐synuclein (αSyn) accumulation in cholinergic and adrenergic fibers in the skin is a useful biomarker to diagnose idiopathic Parkinson's disease (IPD). It has been widely reported that phosphorylated αSyn (p‐αSyn) deposits in autonomic fibers in IPD are a biomarker in the skin, but other tissue localizations have not been fully investigated.Objective: It has been previously suggested that αSyn aggregates activate peripheral macrophages and that peripheral macrophages ingest pathological αsyn aggregates in aged rats or IPD patients. However, it remains to be elucidated whether peripheral macrophages in the skin of IPD patients accumulate αSyn. We evaluated whether (1) p‐αSyn deposits in dermal macrophages might represent a useful biomarker for IPD and (2) dermal macrophages play a role in the underlying pathogenesis of IPD.Methods: We performed an immunohistological analysis of skin biopsy specimens from IPD patients and controls.Results: We found that (1) p‐αSyn accumulation is present in dermal macrophages in skin biopsy specimens from patients with IPD, (2) not only dermal adrenergic fibers with p‐αSyn deposits but also dermal macrophages with p‐αSyn deposits are useful biomarkers for IPD patients and (3) the number of macrophages was significantly positively correlated with the number of macrophages with p‐αSyn deposits in the dermis of IPD patients.Interpretation: Our results suggest that dermal macrophages, which are innate immune cells, play an important role in IPD patients and are a novel biomarker for IPD.
- 24 June 2022
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 9 (8) , 1136-1146
Open AccessPhosphorylated alpha‐synuclein in Iba1‐positive macrophages in the skin of patients with Parkinson's disease
Background: Increasing evidence suggests that alpha‐synuclein (αSyn) accumulation in cholinergic and adrenergic fibers in the skin is a useful biomarker to diagnose idiopathic Parkinson's disease (IPD). It has been widely reported that phosphorylated αSyn (p‐αSyn) deposits in autonomic fibers in IPD are a biomarker in the skin, but other tissue localizations have not been fully investigated.Objective: It has been previously suggested that αSyn aggregates activate peripheral macrophages and that peripheral macrophages ingest pathological αsyn aggregates in aged rats or IPD patients. However, it remains to be elucidated whether peripheral macrophages in the skin of IPD patients accumulate αSyn. We evaluated whether (1) p‐αSyn deposits in dermal macrophages might represent a useful biomarker for IPD and (2) dermal macrophages play a role in the underlying pathogenesis of IPD.Methods: We performed an immunohistological analysis of skin biopsy specimens from IPD patients and controls.Results: We found that (1) p‐αSyn accumulation is present in dermal macrophages in skin biopsy specimens from patients with IPD, (2) not only dermal adrenergic fibers with p‐αSyn deposits but also dermal macrophages with p‐αSyn deposits are useful biomarkers for IPD patients and (3) the number of macrophages was significantly positively correlated with the number of macrophages with p‐αSyn deposits in the dermis of IPD patients.Interpretation: Our results suggest that dermal macrophages, which are innate immune cells, play an important role in IPD patients and are a novel biomarker for IPD.